AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19094160 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone (10 mg t.i.d.) for 5 days with transdermal rotigotine patch (2 mg (24 h)(-1), 10 cm(2), total drug content 4.5 mg) applied daily for 4 days
Number of subjects: 16
Study 19094160 — intervention group
Group type: COMPARATOR
Intervention: Transdermal rotigotine treatment (2 mg (24 h)(-1), 10 cm(2), total drug content 4.5 mg) applied daily for 4 days
Number of subjects: 16
Study 17557948 — intervention group
Group type: COMPARATOR
Intervention: Standard public health recommendation for PA
Number of subjects: 377
Study 17557948 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast cancer-specific PA print materials
Number of subjects: 377
Study 17557948 — intervention group
Group type: EXPERIMENTAL
Intervention: Step pedometer
Number of subjects: 377
Study 17557948 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of breast cancer-specific print materials and step pedometers
Number of subjects: 377
Study 17557948 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined group
Number of subjects: 377
Study 16284984 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance/consolidation chemotherapy
Number of subjects: 2550
Study 12474702 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolfenamic acid 300 mg
Number of subjects: 192
Study 12474702 — intervention group
Group type: COMPARATOR
Intervention: Pizotifen 1.5 mg
Number of subjects: 192
Study 9809818 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron
Number of subjects: 32
Study 9809818 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide-diphenhydramine
Number of subjects: 32
Study 7665066 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg Fe
Number of subjects: 36
Study 7665066 — intervention group
Group type: EXPERIMENTAL
Intervention: 20,000 IE erythropoietin (rHuEPO) i.v.
Number of subjects: 36
Study 7665066 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 2669626 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir
Number of subjects: 0
Study 2669626 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1091272 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluphenazine decanoate
Number of subjects: 5
Study 1091272 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluspirilene
Number of subjects: 5
Study 1091272 — intervention group
Group type: EXPERIMENTAL
Intervention: Penfluridol
Number of subjects: 5
Study 1091272 — intervention group
Group type: EXPERIMENTAL
Intervention: Perphenazine-enanthate
Number of subjects: 5
Study 1091272 — intervention group
Group type: EXPERIMENTAL
Intervention: Pipothiazine palmitate
Number of subjects: 5
Study 31319234 — intervention group
Group type: EXPERIMENTAL
Intervention: Tunneled external ventricular drainage (T‐EVD)
Number of subjects: 120
Study 31319234 — intervention group
Group type: COMPARATOR
Intervention: Standard external ventricular drainage (S‐EVD)
Number of subjects: 120
Study 28562117 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 (425 mg/capsule, 2 capsules/day)
Number of subjects: 68
Study 28562117 — intervention group
Group type: COMPARATOR
Intervention: Soybean isoflavones (54.4 mg/tablet, 2 tablets/day)
Number of subjects: 68
Study 25573393 — intervention group
Group type: EXPERIMENTAL
Intervention: Transtibial pull-out technique using 1 transtibial bone tunnel
Number of subjects: 10
Study 25573393 — intervention group
Group type: EXPERIMENTAL
Intervention: Transtibial pull-out technique using 2 transtibial bone tunnels
Number of subjects: 10
Study 23680628 — intervention group
Group type: EXPERIMENTAL
Intervention: Povidone-iodine 1.0%
Number of subjects: 271
Study 23680628 — intervention group
Group type: EXPERIMENTAL
Intervention: Povidone-iodine 5.0%
Number of subjects: 271
Study 23680628 — intervention group
Group type: EXPERIMENTAL
Intervention: Povidone-iodine 10.0%
Number of subjects: 271
Study 23680628 — intervention group
Group type: COMPARATOR
Intervention: Control smear (no-surgery eye)
Number of subjects: 271
Study 21806580 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen inhalation (8 L/min via face mask for 2 h)
Number of subjects: 450
Study 21806580 — intervention group
Group type: COMPARATOR
Intervention: Room air (control group)
Number of subjects: 450
Study 21806580 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen inhalation
Number of subjects: 450
Study 19336539 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol infusion at 3 mg kg(‐1) h(‐1)
Number of subjects: 12
Study 19336539 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol infusion at 6 mg kg(‐1) h(‐1)
Number of subjects: 12
Study 16927064 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine supplementation (0.2 g/kg per day)
Number of subjects: 60
Study 16927064 — intervention group
Group type: COMPARATOR
Intervention: Control (isonitrogenous amino acid)
Number of subjects: 60
Study 16927064 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine supplementation
Number of subjects: 60
Study 16927064 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 60
Study 15326084 — intervention group
Group type: EXPERIMENTAL
Intervention: Low sodium diet
Number of subjects: 117
Study 15326084 — intervention group
Group type: COMPARATOR
Intervention: High sodium diet
Number of subjects: 117
Study 15326084 — intervention group
Group type: EXPERIMENTAL
Intervention: Trp460Trp genotype
Number of subjects: 117
Study 14636099 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-minute rest interval
Number of subjects: 17
Study 14636099 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-minute rest interval
Number of subjects: 17
Study 14636099 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-minute rest interval
Number of subjects: 17
Study 14636099 — intervention group
Group type: COMPARATOR
Intervention: Different rest intervals (1, 3, 5 minutes)
Number of subjects: 17
Study 10220009 — intervention group
Group type: COMPARATOR
Intervention: 5-HT uptake in platelets
Number of subjects: 30
Study 10220009 — intervention group
Group type: COMPARATOR
Intervention: 5-HT uptake sites density (Bmax)
Number of subjects: 30
Study 7782904 — intervention group
Group type: EXPERIMENTAL
Intervention: Bread baked with high concentration of Na‐propionate
Number of subjects: 0
Study 7782904 — intervention group
Group type: EXPERIMENTAL
Intervention: Breads baked with sourdough, lactic acid, and Na‐propionate
Number of subjects: 0
Study 7782904 — intervention group
Group type: EXPERIMENTAL
Intervention: Breads containing lactic acid
Number of subjects: 0
Study 7782904 — intervention group
Group type: COMPARATOR
Intervention: All bread products
Number of subjects: 0
Study 2140987 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal angioplasty (PTA)
Number of subjects: 36
Study 2140987 — intervention group
Group type: COMPARATOR
Intervention: Supervised exercise therapy
Number of subjects: 36
Study 428228 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin vaginal suppositories
Number of subjects: 77
Study 428228 — intervention group
Group type: COMPARATOR
Intervention: Vacuum aspiration by Kahrman catheter
Number of subjects: 77
Study 31773165 — intervention group
Group type: EXPERIMENTAL
Intervention: A2M (a2 Milk; exclusively containing A2 β-casein with lactose)
Number of subjects: 40
Study 31773165 — intervention group
Group type: COMPARATOR
Intervention: CON (conventional milk; containing A1 and A2 β-casein and lactose)
Number of subjects: 40
Study 31773165 — intervention group
Group type: EXPERIMENTAL
Intervention: LF-CON (lactose-free conventional milk; containing A1 and A2 β-casein without lactose)
Number of subjects: 40
Study 31773165 — intervention group
Group type: EXPERIMENTAL
Intervention: NLDI subjects (irrespective of milk type)
Number of subjects: 40
Study 31070741 — intervention group
Group type: EXPERIMENTAL
Intervention: UCare intervention (website + booklet)
Number of subjects: 1103
Study 31070741 — intervention group
Group type: COMPARATOR
Intervention: Delayed Treatment control
Number of subjects: 1103
Study 27798052 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 18140
Study 27798052 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 18140
Study 27798052 — intervention group
Group type: EXPERIMENTAL
Intervention: CRNM bleeding
Number of subjects: 18140
Study 25823768 — intervention group
Group type: EXPERIMENTAL
Intervention: Transoral incisionless fundoplication (TIF)
Number of subjects: 60
Study 25823768 — intervention group
Group type: COMPARATOR
Intervention: Proton pump inhibitors (PPI)
Number of subjects: 60
Study 23605506 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl sublingual spray 100 μg
Number of subjects: 53
Study 23605506 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl sublingual spray 200 μg
Number of subjects: 53
Study 23605506 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl sublingual spray 400 μg
Number of subjects: 53
Study 23605506 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl sublingual spray 600 μg
Number of subjects: 53
Study 23605506 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl sublingual spray 800 μg
Number of subjects: 53
Study 21970565 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based tutorials with behavior modification strategies for nutrition, exercise, and other behaviors
Number of subjects: 121
Study 21970565 — intervention group
Group type: COMPARATOR
Intervention: Standard information (control group)
Number of subjects: 121
Study 19788018 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab (Xolair)
Number of subjects: 0
Study 19788018 — intervention group
Group type: COMPARATOR
Intervention: Nonomalizumab
Number of subjects: 0
Study 16625008 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Number of subjects: 180
Study 16625008 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study 14739758 — intervention group
Group type: EXPERIMENTAL
Intervention: Active learning session (30 minutes of direct content delivery)
Number of subjects: 0
Study 14739758 — intervention group
Group type: COMPARATOR
Intervention: Didactic lecture (60 minutes of direct content delivery)
Number of subjects: 0
Study 14739758 — intervention group
Group type: EXPERIMENTAL
Intervention: Both teaching methods
Number of subjects: 0
Study 11704752 — intervention group
Group type: EXPERIMENTAL
Intervention: One-week application of terbinafine cream
Number of subjects: 43
Study 11704752 — intervention group
Group type: COMPARATOR
Intervention: Four-week application of terbinafine cream
Number of subjects: 43
Study 9163285 — intervention group
Group type: EXPERIMENTAL
Intervention: TIPS (n = 41)
Number of subjects: 100
Study 9163285 — intervention group
Group type: COMPARATOR
Intervention: Sclerotherapy (n = 39)
Number of subjects: 100
Study 9163285 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study 7959537 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoximone (E) 1 to 9 micrograms/kg/min, increments of 1 microgram/kg/min every 2 min
Number of subjects: 10
Study 7959537 — intervention group
Group type: COMPARATOR
Intervention: Dobutamine (D) 5 to 40 micrograms/kg/min, increments of 5 micrograms/kg/min every 3 min
Number of subjects: 10
Study 31322804 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiogel® moisturizing creams (three test products)
Number of subjects: 0
Study 31322804 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 30236246 — intervention group
Group type: EXPERIMENTAL
Intervention: LIA with ropivacaine 0.2% for postoperative analgesia
Number of subjects: 80
Study 30236246 — intervention group
Group type: COMPARATOR
Intervention: FNB with LIA of the posterior capsule
Number of subjects: 80
Study 26554459 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring (cardiorespiratory monitoring, i.e., electrocardiogram)
Number of subjects: 60
Study 26554459 — intervention group
Group type: COMPARATOR
Intervention: Nonmonitoring (no cardiorespiratory monitoring)
Number of subjects: 60
Study 23897949 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback respiratory training
Number of subjects: 22
Study 23897949 — intervention group
Group type: COMPARATOR
Intervention: Comprehensive rehabilitation therapy
Number of subjects: 22
Study 22348643 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual Chest Therapy (MCT)
Number of subjects: 658
Study 19962772 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interval training for 6 months
Number of subjects: 40
Study 19962772 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 40
Study 18427409 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental conditioning program (polygon training with sprint-runs and ball drills)
Number of subjects: 48
Study 18427409 — intervention group
Group type: COMPARATOR
Intervention: Traditional conditioning (straight-line running with stretching exercises)
Number of subjects: 48
Study 16012284 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (5‐20 mg/d)
Number of subjects: 1152
Study 16012284 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (3‐15 mg/d)
Number of subjects: 1152
Study 16012284 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (10‐20 mg/d)
Number of subjects: 1152
Study 16012284 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (4‐12 mg/d)
Number of subjects: 1152
Study 16012284 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1152
Study 12970201 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump coronary artery bypass (OPCAB)
Number of subjects: 211
Study 12970201 — intervention group
Group type: COMPARATOR
Intervention: On-pump coronary artery bypass (CABG)
Number of subjects: 211
Study 11789190 — intervention group
Group type: EXPERIMENTAL
Intervention: HANS treatment (4 treatments of 30 min each for the first 3 days, twice a day for 3 more days, and once a day for 7 days; total 15 days)
Number of subjects: 181
Study 11789190 — intervention group
Group type: COMPARATOR
Intervention: Control group (electrodes placed at acupoints without electrical stimulation)
Number of subjects: 181
Study 8861236 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 g glucose
Number of subjects: 28
Study 8861236 — intervention group
Group type: COMPARATOR
Intervention: 27.3 mg saccharin
Number of subjects: 28
Study 1623692 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (80 mg every 8 hours for 6 days)
Number of subjects: 10
Study 1623692 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 6704647 — intervention group
Group type: EXPERIMENTAL
Intervention: Iohexol (40 ml, 350 mg I/ml)
Number of subjects: 0
Study 6704647 — intervention group
Group type: COMPARATOR
Intervention: Metrizamide
Number of subjects: 0
Study 30364933 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene expression signatures associated with HR+ HPV and CIN1/2/3
Number of subjects: 83
Study 30364933 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene expression signatures associated with HR HPV-free and cervical histopathology-free
Number of subjects: 83
Study 30364933 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene expression signatures associated with HR+ HPV and cervical histopathology-free
Number of subjects: 83
Study 30364933 — intervention group
Group type: COMPARATOR
Intervention: LEEP tissue gene expression
Number of subjects: 83
Study 29126319 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol 300,000 IU initially, then 1400 IU cholecalciferol and 500 mg of calcium daily for 150 days
Number of subjects: 330
Study 26554304 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention Bias Modification (ABM) training
Number of subjects: 41
Study 26554304 — intervention group
Group type: COMPARATOR
Intervention: Placebo training (active control)
Number of subjects: 41
Study 26554304 — intervention group
Group type: EXPERIMENTAL
Intervention: ABM training
Number of subjects: 41
Study 25540496 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-stretching exercise for 4 weeks
Number of subjects: 81
Study 22250851 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisession computerized interpretation modification program (IMP), n = 23
Number of subjects: 49
Study 22250851 — intervention group
Group type: COMPARATOR
Intervention: Interpretation control condition (ICC), n = 26
Number of subjects: 49
Study 18818024 — intervention group
Group type: EXPERIMENTAL
Intervention: Luteal phase
Number of subjects: 25
Study 18818024 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase-related variability in premenstrual symptomatology
Number of subjects: 25
Study 18818024 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase-related variability in urge to smoke
Number of subjects: 25
Study 17095559 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin (3.6 mg every 4 weeks)
Number of subjects: 22
Study 17095559 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 17095559 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin
Number of subjects: 22
Study 17095559 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin and Placebo
Number of subjects: 22
Study 15842551 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg moxifloxacin IV as a 1 h infusion
Number of subjects: 9
Study 15842551 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg moxifloxacin IV as a 1 h infusion with oral activated charcoal (5 g before infusion, 5 g after infusion, 10 g at 2, 4, and 8 h)
Number of subjects: 9
Study 15842551 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg oral moxifloxacin with activated charcoal (10 g 15 min before and at 2, 4, and 8 h after drug administration)
Number of subjects: 9
Study 12372724 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 5732
Study 12372724 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormonal therapies
Number of subjects: 5732
Study 12372724 — intervention group
Group type: EXPERIMENTAL
Intervention: Biological therapy
Number of subjects: 5732
Study 12372724 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 5732
Study 9653476 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhinocort Aqua 128 micrograms
Number of subjects: 138
Study 9653476 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhinocort Turbuhaler 140 micrograms
Number of subjects: 138
Study 9653476 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study 8129189 — intervention group
Group type: EXPERIMENTAL
Intervention: Picotamide, 300 mg three times a day
Number of subjects: 20
Study 8129189 — intervention group
Group type: COMPARATOR
Intervention: Placebo (three identical tablets each day)
Number of subjects: 20
Study 2782273 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine GITS (30, 60, or 90 mg once daily)
Number of subjects: 63
Study 2782273 — intervention group
Group type: COMPARATOR
Intervention: Sustained-release propranolol (80, 160, or 240 mg once daily)
Number of subjects: 63
Study 786662 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (Tenormin, ICI 66 082)
Number of subjects: 30
Study 786662 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 30
Study 786662 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 31189517 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral semaglutide (14 mg once daily for 26 weeks)
Number of subjects: 324
Study 31189517 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 324
Study 31189517 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral semaglutide
Number of subjects: 324
Study 28784922 — intervention group
Group type: EXPERIMENTAL
Intervention: Fitbit One
Number of subjects: 21
Study 25882235 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids derived from fish oil
Number of subjects: 131
Study 25882235 — intervention group
Group type: COMPARATOR
Intervention: Oil-based placebo
Number of subjects: 131
Study 23442271 — intervention group
Group type: EXPERIMENTAL
Intervention: Agility Training (AT)
Number of subjects: 41
Study 23442271 — intervention group
Group type: COMPARATOR
Intervention: Traditional Military Physical Training (PT)
Number of subjects: 41
Study 21870954 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient programme using cognitive-behavioural techniques (experimental group, n=7)
Number of subjects: 12
Study 21870954 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in size)
Number of subjects: 12
Study 18298423 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 0.005% ointment (FP) twice daily during the acute phase and twice weekly during the maintenance phase
Number of subjects: 90
Study 18298423 — intervention group
Group type: COMPARATOR
Intervention: Placebo ointment twice weekly on consecutive days
Number of subjects: 90
Study 17889314 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion + nicotine patch
Number of subjects: 58
Study 17889314 — intervention group
Group type: COMPARATOR
Intervention: Nicotine patch
Number of subjects: 58
Study 17889314 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinued cigarettes
Number of subjects: 58
Study 15464333 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg sildenafil
Number of subjects: 60
Study 15464333 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg vardenafil
Number of subjects: 60
Study 15464333 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg vardenafil
Number of subjects: 60
Study 15464333 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg tadalafil
Number of subjects: 60
Study 15464333 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg tadalafil
Number of subjects: 60
Study 15464333 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg tadalafil
Number of subjects: 60
Study 11470383 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (6-week course)
Number of subjects: 98
Study 11470383 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 9725545 — intervention group
Group type: EXPERIMENTAL
Intervention: [14C] irbesartan orally as a solution (50 mg)
Number of subjects: 18
Study 9725545 — intervention group
Group type: EXPERIMENTAL
Intervention: [14C] irbesartan orally as a solution (150 mg)
Number of subjects: 18
Study 9725545 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan capsule (50 mg)
Number of subjects: 18
Study 9725545 — intervention group
Group type: EXPERIMENTAL
Intervention: [14C] irbesartan as a 30‐minute intravenous infusion (50 mg)
Number of subjects: 18
Study 9725545 — intervention group
Group type: EXPERIMENTAL
Intervention: All routes of administration
Number of subjects: 18